This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), McKesson (MCK) and Biohaven Ltd. (BHVN)

Tipranks - Tipranks - Fri May 29, 6:04AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Phreesia (PHR), McKesson (MCK) and Biohaven Ltd. (BHVN).

Memorial Day Sale – Claim 70% Off TipRanks

Phreesia (PHR)

Wells Fargo analyst Stan Berenshteyn reiterated a Hold rating on Phreesia today and set a price target of $9.00. The company’s shares closed last Wednesday at $9.13.

According to TipRanks.com, Berenshteyn is ranked 0 out of 5 stars with an average return of -9.6% and a 44.9% success rate. Berenshteyn covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Omada Health, Inc., and GoodRx Holdings. ;'>

Currently, the analyst consensus on Phreesia is a Moderate Buy with an average price target of $14.14, a 57.8% upside from current levels. In a report issued on May 14, Barclays also downgraded the stock to Hold with a $10.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

McKesson (MCK)

Bank of America Securities analyst Allen Lutz maintained a Buy rating on McKesson today and set a price target of $900.00. The company’s shares closed last Wednesday at $756.47.

According to TipRanks.com, Lutz is a 5-star analyst with an average return of 10.2% and a 64.1% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Definitive Healthcare Corp, and Hims & Hers Health. ;'>

Currently, the analyst consensus on McKesson is a Strong Buy with an average price target of $946.91, which is a 25.5% upside from current levels. In a report issued on May 14, Morgan Stanley also reiterated a Buy rating on the stock with a $966.00 price target.

Biohaven Ltd. (BHVN)

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Biohaven Ltd., with a price target of $18.00. The company’s shares closed last Wednesday at $11.29.

According to TipRanks.com, Flynn is a 5-star analyst with an average return of 9.7% and a 56.7% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Vertex Pharmaceuticals, and Intellia Therapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biohaven Ltd. with a $19.60 average price target.

Read More on PHR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).